The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 30 March 2026•Updated 31 March 2026•

1 min read

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion to Expand Rare Disease Portfolio

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The U.S. FDA approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness.

2 months ago

Version History

7 additional sources confirmed this story

Version 32 months ago

Version 22 months ago

What changed: Biogen shifted from organic growth via regulatory approvals to inorganic expansion through a $5.6 billion acquisition of Apellis Pharmaceuticals.

Version 12 months ago

What changed: Identified the drug as Spinraza and the condition as SMA, while adding critical financial context regarding its $1.5 billion annual revenue and its role in Biogen's competitive strategy.

Biogen has reached an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in an all-cash transaction. This strategic move follows the recent FDA approval of a higher-dose formulation of Biogen's Spinraza, a key treatment for Spinal Muscular Atrophy (SMA). The acquisition marks a significant shift for Biogen (BIIB) as it moves from organic growth to inorganic expansion to bolster its rare disease franchise. By integrating Apellis, Biogen aims to diversify its revenue streams and mitigate competition in the specialized drug market. Analysts view the deal as a critical step in extending the company's long-term commercial lifecycle and strengthening its competitive positioning. This multi-billion dollar investment is expected to enhance investor confidence in Biogen's ability to drive sustainable growth through strategic M&A.